Plain-English translation of NCT06918132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immunotherapy drugs called and given before surgery in people with early-stage lung cancer. These medications work by helping your immune system recognize and fight cancer cells. The goal is to shrink the tumor before surgery and improve your chances of recovery.
Currently, many people with early-stage lung cancer go straight to surgery. Doctors want to know if giving this medication beforehand can reduce the amount of cancer remaining and help prevent the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications by IV infusion (through a vein) on the same day, every 3 weeks, for up to 3 treatment cycles. Between cycles, you'll have imaging scans and blood tests to monitor how the treatment is working. After completing the medication cycles, you would have surgery to remove the remaining cancer. Throughout the study, you'll provide blood and tissue samples for research purposes and have follow-up visits to track your health.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States